4-Month Rifapentine-Moxifloxacin Regimen for Drug-Susceptible TB
For adults aged ≥12 years with newly diagnosed drug-susceptible pulmonary tuberculosis who meet eligibility criteria, use the 4-month rifapentine-moxifloxacin regimen (4-HPMZ): 8 weeks of daily rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by 9 weeks of daily rifapentine, isoniazid, and moxifloxacin (total 119 doses within 5 months). 1, 2
Regimen Structure
The 4-month daily treatment consists of:
Intensive Phase (8 weeks/56 doses):
- Rifapentine (RPT)
- Isoniazid (INH)
- Pyrazinamide (PZA)
- Moxifloxacin (MOX)
Continuation Phase (9 weeks/63 doses):
- Rifapentine (RPT)
- Isoniazid (INH)
- Moxifloxacin (MOX)
The intensive phase must be completed within 70 days of treatment initiation, and continuation phase within 84 days of intensive phase completion, for total completion within 5 months 1.
Patient Eligibility Criteria
You can use this regimen if the patient:
- Is aged ≥12 years
- Has drug-susceptible pulmonary TB (confirmed by molecular and phenotypic testing)
- Has normal liver function (ALT/AST <3x upper limit normal, bilirubin <2.5x upper limit normal)
- Has normal renal function (creatinine <2x upper limit normal)
- Has normal potassium (≥3.5 mEq/L)
- Is not pregnant
- Is HIV-negative OR HIV-positive with CD4 count ≥100 cells/mm³ 1, 3
- Has no fluoroquinolone allergy
- Has no preexisting advanced liver disease or end-stage renal disease
Critical exclusion: This regimen was not studied in HIV-positive patients with CD4 counts <100 cells/mm³, and should not be used in this population 3.
Key Monitoring Requirements
The 2022 CDC guidance provides specific monitoring schedules 1:
Baseline assessments:
- Sputum for rapid molecular testing (resistance to INH, PZA, RIF, fluoroquinolones)
- Sputum AFB smear and culture
- Phenotypic drug susceptibility testing (must include rifapentine, INH, PZA, moxifloxacin)
- Chest radiograph
- Comprehensive metabolic panel (ALT, AST, bilirubin, alkaline phosphatase, creatinine)
- Electrolytes (potassium, calcium, magnesium)
- Platelet count
- HIV testing
Monthly monitoring during treatment:
- Sputum AFB smear and culture until two consecutive negatives
- Weight assessment
- Symptom review and adverse event monitoring
- Laboratory testing (liver function, platelets, creatinine, electrolytes) at weeks 4,8,12, and 16
Evidence Quality and Strength
The most recent 2025 ATS/CDC/ERS/IDSA guidelines provide a strong recommendation for this regimen based on clinical trial data demonstrating non-inferiority to the standard 6-month regimen 2. The 2022 CDC interim guidance established the framework for implementation in the United States 1.
Important Clinical Caveats
Real-world implementation challenges exist: A 2025 study from NYC Health Department TB clinics found that among 284 eligible patients, only 40 (14%) were prescribed 4-HPMZ, with just 36% completing treatment. The primary reason for discontinuation was adverse events (42% of those who started) 4. This highlights the importance of:
- Careful patient selection
- Intensive monitoring for adverse events
- Having contingency plans for regimen modification
- Ensuring rifapentine availability (a known barrier) 5
Drug interactions matter: Moxifloxacin can prolong QT interval. Rifapentine has significant drug interactions, particularly with antiretrovirals, which is why careful consideration is needed in HIV-positive patients 5.
Alternative for paucibacillary disease: The 4-month regimen may also be used for smear-negative, culture-negative, noncavitary TB, though this was not specifically studied in the pivotal trial 1.
When NOT to Use This Regimen
Switch to standard 6-month therapy or individualized longer regimens if:
- Extrapulmonary TB (except pleural or lymph node TB)
- Drug resistance detected to any component
- Severe hepatic or renal dysfunction develops
- Intolerable adverse events occur
- HIV-positive with CD4 <100 cells/mm³
- Pregnancy occurs during treatment
- Patient unable to complete within the specified timeframe
The evidence strongly supports this regimen as equally effective as 6-month therapy with the advantage of shorter duration, but successful implementation requires rigorous patient selection, monitoring infrastructure, and management of adverse events 1, 2.